Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond.

Kanaan, Zeyad; Kloecker, Goetz H; Paintal, Ajit; Perez, Cesar A

Kanaan, Zeyad; Kloecker, Goetz H; Paintal, Ajit; Perez, Cesar A.

Afiliação

Kanaan Z; Division of Medical Oncology and Hematology, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA.
Kloecker GH; Division of Medical Oncology and Hematology, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA.
Paintal A; Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
Perez CA; Division of Medical Oncology and Hematology, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA.

Onco Targets Ther ; 8: 885-92, 2015.

Article em En | MEDLINE | ID: mdl-25945060

Palavras-chave

ALK inhibitor; EML4-ALK rearrangement; Vysis; crizotinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Onco Targets Ther Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google